To circumvent this issue, we focused on BtAdVs, which did not cross-react with anti-CAdVs neutralizing antibodies, and constructed a genetically modified BtAdV, in which a tumor-specific promoter was accommodated for E1A gene expression, which is essential for viral replication. The gene discussed is DHTKD1; the disease is neoplasm.